EGFR and non-small cell lung carcinoma: The benefit of osimertinib treatment was also found to be extended to the subgroup of Chinese EGFR T790M mutation positive NSCLC patients with brain/leptomeningeal metastases reporting a median PFS of 11.0 months (95% CI 9.7–12.4).